论文部分内容阅读
Mylotarg(Gemtuzumab Ozogamicin,CMA-676)是人源化抗CD33单克隆抗体与抗肿瘤抗生素Calicheamicin偶联而成的一个新的抗体导向化疗药药。作者报告单用该药治疗第一次复发未治CD33~+急性髓系白血病(AML)的疗效及安全性。 方法 北美及欧洲多中心研究观察142(男84、女58)例,CD33~+AML(CD33~+白血病细胞大于80％)第一次复发患者,中位年龄61(22～84)岁。Mylotarg每次9mg/m~2,持续静滴2h,每次用药间隔不少于14天,不超过28天,最多
Mylotarg (Gemtuzumab Ozogamicin, CMA-676) is a new antibody-directed chemotherapeutic agent that is a combination of humanized anti-CD33 monoclonal antibody and antitumor antibiotic Calicheamicin. The authors report the efficacy and safety of the drug alone in the treatment of first-episode non-CD33 + acute myeloid leukemia (AML). Methods A total of 142 (male 84, female 58) cases of multi-center study in North America and Europe and 61 patients (22-84 years) with first relapse of CD33 + AML (> 80% of CD33 + leukemia cells) were recruited. Mylotarg each 9mg / m ~ 2, continuous intravenous infusion 2h, each time interval of not less than 14 days, not more than 28 days, up to